These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31005728)

  • 21. Circulating omentin-1 levels and inflammation in polycystic ovary syndrome.
    Franik G; Sadlocha M; Madej P; Owczarek A; Skrzypulec-Plinta V; Plinta R; Chudek J; Olszanecka-Glinianowicz M
    Ginekol Pol; 2020; 91(6):308-312. PubMed ID: 32627151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Platelet-derived microparticles in overweight/obese women with the polycystic ovary syndrome.
    Koiou E; Tziomalos K; Katsikis I; Papadakis E; Kandaraki EA; Panidis D
    Gynecol Endocrinol; 2013 Mar; 29(3):250-3. PubMed ID: 23216335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sexual function and depression in polycystic ovary syndrome: Is it associated with inflammation and neuromodulators?
    Aydogan Kirmizi D; Baser E; Onat T; Demir Caltekin M; Yalvac ES; Kara M; Gocmen AY
    Neuropeptides; 2020 Dec; 84():102099. PubMed ID: 33120204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of a hypocaloric diet with and without exercise training on body composition, cardiometabolic risk profile, and reproductive function in overweight and obese women with polycystic ovary syndrome.
    Thomson RL; Buckley JD; Noakes M; Clifton PM; Norman RJ; Brinkworth GD
    J Clin Endocrinol Metab; 2008 Sep; 93(9):3373-80. PubMed ID: 18583464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome.
    Koiou E; Tziomalos K; Katsikis I; Kandaraki EA; Kalaitzakis E; Delkos D; Vosnakis C; Panidis D
    Gynecol Endocrinol; 2012 Jan; 28(1):20-4. PubMed ID: 21756081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating anti-Müllerian hormone levels in relation to nutritional status and selected adipokines levels in polycystic ovary syndrome.
    Olszanecka-Glinianowicz M; Madej P; Owczarek A; Chudek J; Skałba P
    Clin Endocrinol (Oxf); 2015 Jul; 83(1):98-104. PubMed ID: 25440474
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features.
    Morales AJ; Laughlin GA; Bützow T; Maheshwari H; Baumann G; Yen SS
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2854-64. PubMed ID: 8768842
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Correlation between interleukin-1 and the obesity of polycystic ovary syndrome].
    Yang Y; Qiao J; Li MZ
    Zhonghua Fu Chan Ke Za Zhi; 2012 Jan; 47(1):9-13. PubMed ID: 22455686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of pro-oxidant-antioxidant balance (PAB) and its association with inflammatory cytokines in polycystic ovary syndrome (PCOS).
    Artimani T; Karimi J; Mehdizadeh M; Yavangi M; Khanlarzadeh E; Ghorbani M; Asadi S; Kheiripour N
    Gynecol Endocrinol; 2018 Feb; 34(2):148-152. PubMed ID: 28868943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycoprotein A and B Height-to-Width Ratios as Obesity-Independent Novel Biomarkers of Low-Grade Chronic Inflammation in Women with Polycystic Ovary Syndrome (PCOS).
    Fuertes-Martín R; Moncayo S; Insenser M; Martínez-García MÁ; Luque-Ramírez M; Grau NA; Blanchar XC; Escobar-Morreale HF
    J Proteome Res; 2019 Nov; 18(11):4038-4045. PubMed ID: 31503497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polycystic ovary syndrome is a risk factor for sarcopenic obesity: a case control study.
    McBreairty LE; Chilibeck PD; Gordon JJ; Chizen DR; Zello GA
    BMC Endocr Disord; 2019 Jul; 19(1):70. PubMed ID: 31262307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exercise training improves autonomic function and inflammatory pattern in women with polycystic ovary syndrome (PCOS).
    Giallauria F; Palomba S; Maresca L; Vuolo L; Tafuri D; Lombardi G; Colao A; Vigorito C; Francesco O
    Clin Endocrinol (Oxf); 2008 Nov; 69(5):792-8. PubMed ID: 18505468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of body mass on inflammatory markers and insulin resistance in polycystic ovary syndrome.
    Souza Dos Santos AC; Soares NP; Costa EC; de Sá JC; Azevedo GD; Lemos TM
    Gynecol Endocrinol; 2015 Mar; 31(3):225-8. PubMed ID: 25373529
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Postprandial inflammatory responses after oral glucose, lipid and protein challenges: Influence of obesity, sex and polycystic ovary syndrome.
    Martínez-García MÁ; Moncayo S; Insenser M; Montes-Nieto R; Fernández-Durán E; Álvarez-Blasco F; Luque-Ramírez M; Escobar-Morreale HF
    Clin Nutr; 2020 Mar; 39(3):876-885. PubMed ID: 30975555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diet composition and physical activity in overweight and obese premenopausal women with or without polycystic ovary syndrome.
    Álvarez-Blasco F; Luque-Ramírez M; Escobar-Morreale HF
    Gynecol Endocrinol; 2011 Dec; 27(12):978-81. PubMed ID: 21609197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma plasminogen activator inhibitor-1 levels in the different phenotypes of the polycystic ovary syndrome.
    Koiou E; Tziomalos K; Dinas K; Katsikis I; Kandaraki EA; Tsourdi E; Mavridis S; Panidis D
    Endocr J; 2012; 59(1):21-9. PubMed ID: 21996594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between circulating neuregulin 4 levels and metabolic, aterogenic, and AMH profile of polycystic ovary syndrome.
    Kurek Eken M; Sahin Ersoy G; Yayla Abide C; Sanverdi İ; Devranoglu B; Kutlu T; Çevik Ö
    J Obstet Gynaecol; 2019 Oct; 39(7):975-980. PubMed ID: 31064233
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Roles of LH and insulin resistance in lean and obese polycystic ovary syndrome.
    Grulet H; Hecart AC; Delemer B; Gross A; Sulmont V; Leutenegger M; Caron J
    Clin Endocrinol (Oxf); 1993 Jun; 38(6):621-6. PubMed ID: 8334748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of insulin resistance and plasma levels for visfatin and resistin in obese and non-obese patients with polycystic ovary syndrome.
    Gul OO; Cander S; Gul B; Açıkgoz E; Sarandol E; Ersoy C
    Eur Cytokine Netw; 2015; 26(4):73-8. PubMed ID: 26967765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A three-component cognitive behavioural lifestyle program for preconceptional weight-loss in women with polycystic ovary syndrome (PCOS): a protocol for a randomized controlled trial.
    Jiskoot G; Benneheij SH; Beerthuizen A; de Niet JE; de Klerk C; Timman R; Busschbach JJ; Laven JS
    Reprod Health; 2017 Mar; 14(1):34. PubMed ID: 28264692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.